May 3 |
BofA starts Avidity at buy, cites upcoming clinical data
|
Apr 18 |
To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
|
Apr 4 |
Insider Sell: Avidity Biosciences Inc (RNA) President and CEO Sarah Boyce Sells 28,000 Shares
|
Apr 2 |
Avidity Biosciences files to sell 24.26M common shares for holders
|
Mar 15 |
Insider Sell: CFO Michael Maclean Sells 40,000 Shares of Avidity Biosciences Inc (RNA)
|
Mar 5 |
Avidity Biosciences: Targeting A First Ever Approval In DM1 With Improving Data
|
Mar 5 |
A Closer Look at 5 Analyst Recommendations For Avidity Biosciences
|
Mar 4 |
Top 2% Biotech Avidity Collapses Despite 'Positive' Results In Treating Muscular Dystrophy
|
Mar 4 |
Avidity unveils long-term data in myotonic dystrophy trial
|
Mar 4 |
Avidity Biosciences Announces Positive AOC 1001 Long-term Data Showing Reversal of Disease Progression in People Living with Myotonic Dystrophy Type 1 Across Multiple Endpoints; Same Key Endpoints Agreed for Phase 3 HARBOR™ Trial
|